tiprankstipranks
Trending News
More News >
InflaRx NV (IFRX)
NASDAQ:IFRX

InflaRx (IFRX) AI Stock Analysis

Compare
703 Followers

Top Page

IF

InflaRx

(NASDAQ:IFRX)

Rating:39Underperform
Price Target:
$1.00
▲(23.46%Upside)
InflaRx's stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow issues. Technical analysis supports a bearish outlook with poor market momentum. Valuation metrics further highlight concerns due to the company's unprofitability.
Positive Factors
Financial Stability
The company's cash runway guidance could get extended, with cash, cash equivalents, and marketable securities reported at €65.7M.
Pipeline Progress
Inflarx has completed sub-chronic and chronic toxicology studies with INF904 with no signals identified, which should support long-term dosing in future clinical studies.
Product Potential
Inflarx's INF904 is believed to have a potential best-in-class drug profile compared to Amgen's avacopan, with meaningful commercial opportunities in CSU and HS.
Negative Factors
Clinical Trial Outcome
The Independent Data Monitoring Committee recommended the Phase 3 trial evaluating vilobelimab in PG be stopped due to lack of observed treatment effect.
Development Strategy
IFRX intends to discontinue development of vilobelimab in PG, leading to a shift in focus to other projects.

InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)

InflaRx Business Overview & Revenue Model

Company DescriptionInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
How the Company Makes MoneyInflaRx makes money primarily through the development and potential commercialization of its pipeline of therapeutic candidates targeting the complement system. Revenue streams include potential partnerships with larger pharmaceutical companies for co-development and commercialization, as well as licensing agreements that can provide upfront payments, milestone payments, and royalties on sales. Additionally, as InflaRx progresses its drug candidates through clinical trials and towards potential regulatory approval, the company may receive funding through grants or investment from private and public sources to support its research and development activities.

InflaRx Financial Statement Overview

Summary
InflaRx's financials reflect significant operational and financial challenges. The company is struggling with profitability and cash flow management, evident from negative margins and consistent cash outflows. While the balance sheet shows limited leverage, negative returns and persistent losses are concerning for future financial stability.
Income Statement
35
Negative
InflaRx's income statement shows significant challenges in profitability and revenue growth. The company has been operating at a loss with negative net income and gross profit margins. Although total revenue increased from 2023 to 2024, the net profit margin remains negative, reflecting continued financial strain.
Balance Sheet
40
Negative
The balance sheet highlights high equity levels relative to debt, but the company has been operating with net debt positions, suggesting better liquidity management. However, the return on equity is negative due to persistent net losses, pointing to concerns in generating returns for shareholders.
Cash Flow
30
Negative
InflaRx's cash flow statement indicates consistent negative operating cash flow and free cash flow, suggesting ongoing cash burn issues. The free cash flow to net income ratio is poor, pointing to challenges in converting earnings into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue129.75K165.79K63.09K0.000.000.00
Gross Profit-2.98M-3.15M-469.17K-585.85K-696.14K-664.03K
EBITDA-45.87M-45.55M-42.06M-31.29M-46.90M-32.47M
Net Income-44.72M-46.06M-42.67M-27.04M-45.65M-34.01M
Balance Sheet
Total Assets87.00M76.02M120.21M102.40M125.14M88.22M
Cash, Cash Equivalents and Short-Term Investments65.86M52.84M90.27M81.81M83.41M81.13M
Total Debt702.63K805.09K1.12M1.36M1.43M559.04K
Total Liabilities16.53M14.60M17.63M14.05M19.86M10.35M
Stockholders Equity70.47M61.42M102.58M88.35M105.28M77.86M
Cash Flow
Free Cash Flow-47.75M-48.60M-37.89M-33.91M-39.97M-36.62M
Operating Cash Flow-47.70M-48.56M-37.81M-33.74M-39.94M-36.53M
Investing Cash Flow43.08M52.36M-17.70M19.36M-25.95M21.36M
Financing Cash Flow27.48M386.45K52.99M1.94M61.58M9.17M

InflaRx Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.81
Price Trends
50DMA
1.21
Negative
100DMA
1.30
Negative
200DMA
1.65
Negative
Market Momentum
MACD
-0.11
Negative
RSI
38.13
Neutral
STOCH
45.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Negative. The current price of 0.81 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 1.21, and below the 200-day MA of 1.65, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 38.13 is Neutral, neither overbought nor oversold. The STOCH value of 45.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IFRX.

InflaRx Risk Analysis

InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our success depends on our ability to obtain, maintain, protect, defend and enforce patent, trade secret and other intellectual property protection Q4, 2022
2.
Our manufacturing process is subject to quality control risks and related regulatory requirements Q4, 2022
3.
Failure to maintain compliance with FDA requirements and/or remain in alignment with FDA feedback may prevent or delay the development, marketing or manufacturing of vilobelimab for the treatment of critically ill COVID-19 patients and, potentially, of vilobelimab in ulcerative PG Q4, 2022

InflaRx Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.55B0.30-61.90%2.27%17.11%1.58%
48
Neutral
$58.61M-46.28%-33.00%54.91%
44
Neutral
$61.61M91.63%-55.47%24.92%
39
Underperform
$53.71M-62.38%178.84%-40.60%
$46.82M-67.13%
39
Underperform
$140.31M-73.85%-40.59%
35
Underperform
$86.23M-101.34%21.40%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IFRX
InflaRx
0.81
-0.83
-50.61%
VTGN
VistaGen Therapeutics
2.04
-1.36
-40.00%
CLSD
Clearside Biomedical
0.81
-0.47
-36.72%
RENB
Renovaro Biosciences
0.28
-1.32
-82.50%
CABA
Cabaletta Bio
1.60
-5.45
-77.30%
JSPR
Jasper Therapeutics
6.82
-14.32
-67.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 30, 2025